Roth MKM Maintains Buy on Moleculin Biotech, Maintains $40 Price Target
Portfolio Pulse from Benzinga Newsdesk
Roth MKM analyst Jonathan Aschoff has maintained a Buy rating on Moleculin Biotech (NASDAQ:MBRX) with a continued price target of $40.
April 12, 2024 | 4:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Roth MKM reaffirms a Buy rating and a $40 price target on Moleculin Biotech, indicating a positive outlook on the stock.
The maintenance of a Buy rating and a significant price target by a reputable analyst suggests a strong conviction in the stock's potential. This endorsement could positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100